SPOTLIGHT THERAPEUTICS
TAGE-201, an antibody-directed CRISPR gene editor therapeutic for intratumoral delivery to knockout ADAR in tumor microenvironment immune cells
- Sector
- Biotech
- Headquarters
- Hayward, CA
- Founded
- 2017
- Latest Form D
- $32.2M, Jan 2022
- Total capital
- $62.6M
- Federal grants
- $1M
- 1 award · 2023
- Rank in peer group#286 of 326
- Private capital raised
- $61.6M
- 4 Form D · last Jan 2022
- 58 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 40 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · In vivo delivery of Ab-directed CRISPR ribonucleoproteins for anal cancer immunotherapy$1M
- Private capital raisedForm D · SEC · 4th filing$32.2M
- Private capital raisedForm D · SEC · 3rd filing$15.2M
- Private capital raisedForm D · SEC · 2nd filing$6.9M
- Private capital raisedForm D · SEC · 1st filing$7.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Mary HaakFrendschoResearcherExecutive Officer, DirectorLinked by $1M in grants as PI
- Mary Haak-FrendschoResearcherExecutive Officer, DirectorLinked by $1M in grants as PI
- Alexander David MarsonDirectorNamed in SEC Form D filings
- Blake David ByersDirectorNamed in SEC Form D filings
- JACOB CORNDirectorNamed in SEC Form D filings
- Krishna David YeshwantDirectorNamed in SEC Form D filings
Show all 7 people
- Patrick David HsuDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 40- PendingGuide Rnas And Uses ThereofUSPTOApplication 18640660
- PendingAdar Specific Guide Rnas And Uses ThereofUSPTOApplication 18481874
- PendingNucleic Acid Binding Protein Formulations And Uses ThereofUSPTOApplication 18339859
Show all 40 patent records
- Guide Rnas And Uses ThereofDec 12, 2024 · Application 18640660Pending
- Adar Specific Guide Rnas And Uses ThereofOct 3, 2024 · Application 18481874Pending
- Nucleic Acid Binding Protein Formulations And Uses ThereofJun 27, 2024 · Application 18339859Pending
- Methods And Compositions For Nucleic Acid-guided Nuclease Cell Targeting ScreenFeb 3, 2022 · Application 17507324Pending
- Targeted Active Gene Editing Agent And Methods Of UseJan 13, 2022 · Application 17480913Pending
- Targeted Active Gene Editing Agent And Methods Of UseJan 6, 2022 · Application 17481056Pending
- Immune Response Specific Guide Rnas And Uses ThereofApplication PCTUS2023060675Pending
- Transcription Factor Specific Guide Rnas And Uses ThereofApplication PCTUS2023060688Pending
- Guide Rnas And Uses ThereofApplication PCTUS2022078549Pending
- CD11A Tage Compositions And Uses ThereofApplication 63378487Pending
- CD11A Tage Compositions And Uses ThereofApplication 63378491Pending
- PTPN2 Specific Guide Rnas And Uses ThereofApplication PCTUS2022074479Pending
- ZC3H12A (REGNASE-1) Specific Guide Rnas And Uses ThereofApplication PCTUS2022074475Pending
- Adar Specific Guide Rnas And Uses ThereofApplication PCTUS2022071555Pending
- Adar Specific Guide Rnas And Uses ThereofApplication 63362500Pending
- Transcription Factor Specific Guide Rnas And Uses ThereofApplication 63266744Pending
- Immune Response Specific Guide Rnas And Uses ThereofApplication 63266742Pending
- Nucleic Acid Binding Protein Formulations And Uses ThereofApplication PCTUS2021073105Pending
- Guide Rnas And Uses ThereofApplication 63271065Pending
- Compositions And Methods For Screening Cell Internalizing AgentsApplication PCTUS2021049814Pending
- PTPN2 Specific Guide Rnas And Uses ThereofApplication 63228842Pending
- ZC3H12A (REGNASE-1) Specific Guide Rnas And Uses ThereofApplication 63228834Pending
- Adar Specific Guide Rnas And Uses ThereofApplication 63170828Pending
- Compositions And Methods For Gene EditingApplication 63130185Pending
- Nucleic Acid Binding Protein Formulations And Uses ThereofApplication 63130170Pending
- Methods And Compositions For Nucleic Acid-guided Nuclease Cell Targeting ScreenApplication PCTUS2020059149Pending
- Compositions And Methods For Nucleoprotein Targeting And ExpressionApplication PCTUS2020052791Pending
- Compositions And Methods For Screening Cell Internalizing AgentsApplication 63077042Pending
- Methods And Compositions For Nucleic Acid-guided Nuclease Cell Targeting ScreenApplication PCTUS2020029864Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication PCTUS2020024289Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication PCTUS2020024249Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication 62976827Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication 62976790Pending
- Methods And Compositions For Nucleic Acid-guided Nuclease Cell Targeting ScreenApplication 62930888Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication 62913034Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication 62913008Pending
- Compositions And Methods For Nucleoprotein Targeting And ExpressionApplication 62905906Pending
- Methods And Compositions For Nucleic Acid-guided Nuclease Cell Targeting ScreenApplication 62838053Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication 62822542Pending
- Targeted Active Gene Editing Agent And Methods Of UseApplication 62822529Pending
Related companies, and why
- THELIUM THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
- GENMA BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- OAK RIDGE THERAPEUTIC DISCOVERY (ORRXD), LLCSimilar federal contract value in Biotech · null in contracts
- AIMMAX THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- Dianomi Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- QENTOROS LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .